Janoshik Analytical — Independent Peptide Testing Explained | Regena

Janoshik Analytical is an EU-based independent analytical laboratory specialising in research-peptide and small-molecule analysis. The laboratory is operationally independent from peptide manufacturers and suppliers, which is the essential property that gives its reports weight: a Janoshik COA carries no commercial incentive to over-report purity or under-report related impurities.

Janoshik routinely publishes its analytical methods, instrumentation and acceptance criteria, and its reports use a consistent layout that is easily cross-referenced against the batch number on the vial cap. Across the research-peptide industry, a Janoshik report is treated as the minimum credible evidence that a batch has been independently verified.

A standard Janoshik peptide report contains: the batch identifier, the requested compound, the HPLC chromatogram with peak integration, the main-peak purity percentage, the related-impurities profile, the mass-spectrometry chromatogram with theoretical and measured molecular weight, the water (Karl Fischer) content, and the analyst's signature with the report date.

The HPLC chromatogram is the single most important panel: it shows the main peak (the target peptide), the area under that peak as a percentage of total integrated peak area, and the secondary peaks (the related impurities). The mass-spectrometry panel confirms identity — that the main peak is in fact the compound named on the label and not a same-mass-region impurity or a truncated sequence.

Every Regena batch is sent to Janoshik (or, where batch chemistry calls for an orthogonal method, to a second independent laboratory) before any vial is released to dispatch. The Janoshik COA is matched against the batch number printed on the vial cap, archived on the Regena lab reports page, and shipped with the order so the receiving laboratory can re-verify the chain of custody on arrival.

Regena's minimum specification for batch release is ≥99.0% HPLC main-peak purity with matching mass-spectrometry molecular weight and water content within the published specification for the compound. Batches that do not meet the specification are not released, regardless of supply pressure.

A receiving researcher should perform three checks before reconstitution: (1) the batch number on the vial cap matches the batch number on the Janoshik report; (2) the report date is within the shelf-life window for the compound; (3) the report identifies the correct compound at the correct molecular weight.

If any of those three fail, do not reconstitute the vial — contact Regena consultations and the team will replace the batch and investigate the discrepancy. The cross-reference takes under a minute and is the single best protection against handling a mis-labelled or mis-shipped vial.

Janoshik is not the only credible independent peptide laboratory — Anresco, Auriga Research, and several university-hosted core facilities also produce credible COAs. The advantage of Janoshik is consistency: the report format is the same across suppliers and across years, which makes cross-supplier batch comparison straightforward.

Regena occasionally uses an orthogonal laboratory when batch chemistry calls for a second-instrument confirmation, when the receiving institution has a specific accredited-laboratory requirement, or when Janoshik's queue would delay release beyond the project window. The default remains Janoshik for the cross-supplier comparability it offers.

A Janoshik COA is an analytical report, not a sterility certificate, not a clinical authorisation and not a Material Safety Data Sheet. The report covers chemical identity, purity and related impurities for the analysed sample; it does not certify that the rest of the batch is sterile, does not authorise human use, and does not replace institutional ethics or biosafety procedures.

Regena issues sterility, MSDS, CoO and CoC documentation separately on request — most commonly for institutional buyers operating under formal procurement systems. The Janoshik COA sits alongside that documentation, not as a substitute for it.

Every Regena batch COA is published on the /coa lab reports page, indexed by compound and batch number. New batches appear within 24 hours of independent release. The same COA is also bundled with the shipment, printed and electronic, so the receiving researcher can confirm the report before reconstitution.

If a batch number printed on a Regena vial cannot be found on the /coa page, contact consultations immediately — that is a chain-of-custody flag and the Regena team will replace the batch while the discrepancy is investigated.

Research-peptide supply has matured fast over the past three years and so has the pressure on suppliers to short-cut analytical verification. Supplier-funded in-house COAs are the most common short-cut: they look like a Janoshik report at a glance but the analytical laboratory is not commercially independent from the supplier, which removes the property that gives a third-party COA its weight.

Regena's position is straightforward: a batch without an independent COA does not ship. Janoshik is the default, an orthogonal independent laboratory is the fallback, and the COA travels with every shipment to every research jurisdiction Regena serves.